RCT | Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström’s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström’s Macroglobulinemia – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Addition of Bortezomib to First-Line Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia – The ASCO Post